A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. (Q33426559)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

object named as

Frede Donskov

9

0 references

author name string

Anne V Soerensen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Poul F Geertsen

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ib J Christensen

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gregers G Hermann

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Niels V Jensen

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kirsten Fode

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Astrid Petersen

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rickard Sandin

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

8 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Acta Oncologica

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

341-348

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Moving towards dose individualization of tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Diuretic-induced hyponatremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819832

21 June 2018

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1091499

21 January 2018

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1091499

21 January 2018

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1091499

21 January 2018

Impact of immune parameters on long-term survival in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1091499

21 January 2018

IL-6 plays an essential role in neutrophilia under inflammation.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1091499

21 January 2018

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1091499

21 January 2018

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26449266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26449266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26449266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26449266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26449266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mild hyponatremia is associated with an increased risk of death in an ambulatory setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/26449266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26449266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/0284186X.2015.1091499

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33426559&oldid=1948978390"